FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection
- 13 October 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 49 (10) , 1372-1377
Abstract
Objectives: The multidrug regimen with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is widely used for recurrent pancreatic cancer after pancreatic resection. However, there are concerns about severe toxicities and poor tolerability of FOLFIRINOX in these patients because some suffer from surgery-associated malnutrition, weight loss, and diabetes mellitus. We evaluated the toxicity and tolerability of FOLFIRINOX in these patients. Methods: This study was conducted as a secondary analysis of the Japan Adjuvant Study Group of Pancreatic Cancer 06 study, which was a multicenter observational study of FOLFIRINOX for pancreatic cancer in Japan. The toxicity and tolerability of FOLFIRINOX in recurrent disease correlated with those of both the locally advanced and the metastatic disease group. Results: The major grades 3 and 4 toxicities observed in the recurrent and locally advanced or metastatic disease groups were neutropenia (68% vs 63%), febrile neutropenia (4% vs 15%, P = 0.007), thrombocytopenia (4% vs 3%), diarrhea (4% vs 8%), and sensory neuropathy (0% vs 2%). The dose modification and relative dose intensity did not differ markedly between the groups. Conclusions: The toxicity and tolerability of FOLFIRINOX for recurrence after pancreatic resection were similar to those for locally advanced or metastatic disease with appropriate patient selection and dose modifications.Keywords
This publication has 23 references indexed in Scilit:
- Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic SurgeryAnnals of Surgery, 2016
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancerBritish Journal of Cancer, 2016
- Pancreatic Exocrine Insufficiency in Patients With Pancreatic or Periampullary CancerPancreas, 2016
- Pancreatic cancer and FOLFIRINOX: a new era and new questionsCancer Medicine, 2015
- Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic AdenocarcinomaPancreas, 2013
- Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatmentBiomedicine & Pharmacotherapy, 2013
- FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center ExperienceThe Oncologist, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer ResectionJAMA, 2010
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007